• Patients currently receiving NOX66 and chemotherapy
• Six additional clinical trials to start within next 6 months
• Program of planned release in 2017 of data as it becomes available.
Sydney, 2 May 2017: Noxopharm today is pleased to release guidance for the market of anticipated news flow for the next 6 months for its NOX66 clinical trial program. This follows on from the recent release of the Appendix 4C review of the March quarter.
Noxopharm believes that its front-line drug candidate, NOX66, a first-in-class sensitizer of chemotherapy and radiotherapy, has the potential to bring fundamental change to the treatment of many forms of cancer. The Company has embarked on a comprehensive clinical trial program designed to test this belief and to provide clear evidence either way within the next 6 months.
For further information please download PDF attached:
Download this document
